Cancer Cell APC and Open Access: Current Cell Press Pricing, Agreement Reality, and When It Is Worth Paying
Cancer Cell APC is currently $10,400. Hybrid Cell Press pricing, agreement uncertainty, metrics context, and when paying makes sense.
Next step
Choose the next useful decision step first.
Use the guide or checklist that matches this page's intent before you ask for a manuscript-level diagnostic.
Cancer Cell publishing costs and open access options
APC is one cost. Funder mandates, institutional agreements, and access route timing all shape what you actually pay.
What shapes what you pay
- Gold OA at Cancer Cell costs $10,400 USD. Check whether your institution has a read-and-publish agreement that waives this.
- Funder mandates (NIH, Wellcome, UKRI) may require immediate OA — verify compliance before choosing a subscription route.
- Accepted authors typically have 48-72 hours to choose their access route before proofs begin.
When OA is worth the cost
- When your funder or institution requires it — non-compliance can affect future funding.
- When your topic benefits from broad immediate access beyond institutional subscribers.
- Cancer Cell's IF 44.5 means OA papers here have real citation upside.
Quick answer: Cancer Cell currently lists an APC of USD 10,400, excluding taxes, for open-access publication. It remains a hybrid Cell Press journal, so the default subscription route is still $0 to the author. The important 2026 correction is that agreement coverage is no longer safe to describe as universally absent: some Elsevier agreement pages now explicitly include eligible hybrid Cell Press titles, while others still exclude them. For the hub, see the Cancer Cell journal page.
Cancer Cell APC at a glance
Item | Current position |
|---|---|
Journal model | Hybrid |
Current APC | USD 10,400, excluding taxes |
Subscription route | $0 |
OA license choice | Cell Press / Elsevier gold OA license choice applies |
Agreement coverage | Institution-specific, not safe to assume |
2024 impact factor | 44.5 |
CiteScore | 57.7 |
Category rank | 5 / 326 |
Submission to acceptance | 119 days |
If the price looks uncomfortable, the more useful question is usually whether the manuscript is genuinely strong enough for Cancer Cell in the first place. A quick Cancer Cell submission readiness check is worth doing before the APC becomes the main conversation.
What the publisher currently says
The current ScienceDirect journal and insights pages are straightforward:
- open-access APC: USD 10,400, excluding taxes
- subscription publication: no publication fee charged to authors
- the amount paid may be reduced during submission if applicable
The useful nuance sits outside the journal page itself. Elsevier's current agreement pages do not support a blanket statement either way:
- some 2026 agreement pages, including Jisc and Stanford University School of Medicine, explicitly mention eligible hybrid Cell Press titles
- other pages, including CERN, still say authors publishing gold OA in hybrid journals may need to pay because Cell Press is excluded
That means the correct operational rule is simple: do not assume either coverage or exclusion. Ask the library to verify the specific agreement that applies to your institution and acceptance date.
Metrics context behind the APC
Metric | Current figure | Why it matters |
|---|---|---|
Impact Factor | 44.5 | Elite oncology and cancer-biology position |
CiteScore | 57.7 | Strong Scopus signal, not just JIF strength |
Category rank | 5 / 326 | Top-tier field status |
Open-citation trend proxy | 24.69 in 2024 | Still strong after normalization |
Submission to acceptance | 119 days | Long enough that funding clarity matters early |
This is the pricing context that matters. Cancer Cell is not a premium APC on a mid-tier journal. It is a premium APC on one of the most selective cancer-biology venues in the world.
Long-run trend table
Year | Open citation trend proxy |
|---|---|
2017 | 14.30 |
2018 | 14.23 |
2019 | 17.13 |
2020 | 19.50 |
2021 | 20.70 |
2022 | 21.28 |
2023 | 19.83 |
2024 | 24.69 |
The year-over-year move is positive. Cancer Cell's open citation signal is up from 19.83 in 2023 to 24.69 in 2024. That reinforces the basic point: the APC is attached to a journal that still commands field-wide attention.
Agreement and mandate reality
Scenario | What it usually means |
|---|---|
Institution has an Elsevier deal that explicitly includes eligible hybrid Cell Press titles | APC may be covered or heavily subsidized |
Institution has an Elsevier deal but Cell Press is excluded | You may still need to pay the full APC |
Funder requires gold OA and covers it | Cancer Cell remains viable if the paper is truly competitive |
Funder only requires repository compliance | Subscription route may still be the more rational option |
This is the biggest correction to many older Cancer Cell APC pages. The agreement picture is now mixed enough that a generic "no deals cover this" answer is not technically safe.
Readiness check
Run the scan while the topic is in front of you.
See score, top issues, and journal-fit signals before you submit.
What we see in pre-submission review work on Cancer Cell papers
In our pre-submission review work, the expensive mistake is not usually paying the APC. The expensive mistake is paying or budgeting for it before confirming that the manuscript is really Cancer Cell caliber.
What usually works here:
- concept-driven cancer biology
- mechanistic depth with clear disease consequence
- a package that changes how a field reads a pathway, target, or tumor system
What usually creates regret:
- translational work that is strong but not broad enough
- excellent oncology papers that belong in a slightly less concept-heavy venue
- discussing OA budgets before the editorial-fit problem is solved
Submit if / Think twice if
Submit and consider paying for OA if:
- the manuscript is truly competitive for Cancer Cell
- institutional or funder support covers most of the APC
- immediate final-version access matters for visibility, policy, or mandate reasons
- the paper is more concept-defining than merely strong and complete
Think twice if:
- the work is excellent but narrower than Cancer Cell's editorial center
- the institution's agreement status is still unknown
- a subscription route already satisfies the real compliance need
- you would be paying personally without a compelling reason
Practical verdict
For Cancer Cell APC, the current answer is:
- listed APC: $10,400
- subscription route: still free
- agreement coverage: possible at some institutions, absent at others
So the correct sequence is:
- confirm the paper is actually Cancer Cell material
- verify your exact institutional agreement status
- only then decide whether immediate OA is worth funding
Frequently asked questions
Cancer Cell currently lists an Article Publishing Charge of USD 10,400, excluding taxes, for open-access publication. The subscription route remains available at no publication fee to authors.
Yes. Cancer Cell is a hybrid journal, so authors can still publish on the subscription route at no author publication fee.
Sometimes. Official Elsevier agreement pages now show that some institution-specific agreements include eligible hybrid Cell Press titles, while others still exclude Cell Press. Authors should check their own institutional agreement rather than assume coverage either way.
Yes. Elsevier's Cancer Moonshot arrangement says Cell Press journals can publish gold OA with Creative Commons licenses, and standard subscription publication still exists for authors whose compliance route does not require the final version to be immediately open.
It is most defensible when the paper is already truly competitive for Cancer Cell, the institution or funder will cover most of the charge, and immediate final-version access materially helps the project.
Sources
Before you upload
Want the full picture on Cancer Cell?
Scope, selectivity, what editors want, common rejection reasons, and submission context, all in one place.
These pages attract evaluation intent more than upload-ready intent.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Start here
Same journal, next question
- Cancer Cell Submission Guide: What Editors Want, What Gets Rejected, and How to Prepare the Package
- Is Cancer Cell a Good Journal? Impact Factor, Comparison, and Fit Verdict
- Cancer Cell Acceptance Rate: What Authors Can Use
- How to Avoid Desk Rejection at Cancer Cell
- Cancer Cell Review Time: 8-Week Review, 8-10% Acceptance & What Editors Actually Want
- Pre-Submission Review for Oncology Journals: What Cancer Cell and JCO Reviewers Expect
Supporting reads
Want the full picture on Cancer Cell?
These pages attract evaluation intent more than upload-ready intent.